Hanne D Heerkens1, Lisanne van Berkel2, Dorine S J Tseng3, Evelyn M Monninkhof4, Hjalmar C van Santvoort5, Jeroen Hagendoorn6, Inne H M Borel Rinkes6, Irene M Lips7, Martijn Intven1, I Quintus Molenaar8. 1. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Surgery, St Antonius Hospital, Nieuwegein, The Netherlands. 6. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. 7. Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands. 8. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: i.q.molenaar@umcutrecht.nl.
Abstract
BACKGROUND: Surgery for pancreatic cancer yields significant morbidity and mortality risks and survival is limited. Therefore, the influence of complications on quality of life (QoL) after pancreatic surgery is important. This study compares QoL in patients with and without severe complications after surgery for pancreatic (pre-)malignancy. METHODS: This prospective cohort study scored complications after pancreatic surgery according to the Clavien-Dindo system and the definitions of the International Study Group of Pancreatic Surgery. QoL was measured by the RAND36 questionnaire, the European Organization for Research and Treatment of Cancer core questionnaire (QLQ-C30) and the pancreas specific QLQ-PAN26. QoL in patients with severe complications was compared with QoL in patients with no or mild complications over a period of 12 months. Analysis was performed with linear mixed models for repeated measurements. RESULTS: Between March 2012 and July 2016, 137 patients were included. Sixty-eight patients (50%) had at least 1 severe complication. There were no statistically significant and clinically relevant differences between both groups in QoL up to 12 months after surgery. CONCLUSION: In this study, no differences in QoL between patients with and without severe postoperative complications were encountered during the first 12 months after surgery for pancreatic (pre-)malignancy. TRIAL REGISTRATION: http://www.clinicaltrials.gov Identifier: NCT02175992.
BACKGROUND: Surgery for pancreatic cancer yields significant morbidity and mortality risks and survival is limited. Therefore, the influence of complications on quality of life (QoL) after pancreatic surgery is important. This study compares QoL in patients with and without severe complications after surgery for pancreatic (pre-)malignancy. METHODS: This prospective cohort study scored complications after pancreatic surgery according to the Clavien-Dindo system and the definitions of the International Study Group of Pancreatic Surgery. QoL was measured by the RAND36 questionnaire, the European Organization for Research and Treatment of Cancer core questionnaire (QLQ-C30) and the pancreas specific QLQ-PAN26. QoL in patients with severe complications was compared with QoL in patients with no or mild complications over a period of 12 months. Analysis was performed with linear mixed models for repeated measurements. RESULTS: Between March 2012 and July 2016, 137 patients were included. Sixty-eight patients (50%) had at least 1 severe complication. There were no statistically significant and clinically relevant differences between both groups in QoL up to 12 months after surgery. CONCLUSION: In this study, no differences in QoL between patients with and without severe postoperative complications were encountered during the first 12 months after surgery for pancreatic (pre-)malignancy. TRIAL REGISTRATION: http://www.clinicaltrials.gov Identifier: NCT02175992.
Authors: Suvina Amin; Seongjung Joo; Sandra Nolte; Hyun Kyoo Yoo; Nikunj Patel; Hilary F Byrnes; Sara Costa-Cabral; Colin D Johnson Journal: BMC Cancer Date: 2022-05-20 Impact factor: 4.638
Authors: Anastasios Katsourakis; Ioannis Vrabas; Vassilios Papanikolaou; Stylianos Apostolidis; Iosif Chatzis; George Noussios Journal: J Clin Med Res Date: 2018-12-03
Authors: Adithya M Pathanki; Joseph A Attard; Elizabeth Bradley; Sarah Powell-Brett; Bobby V M Dasari; John R Isaac; Keith J Roberts; Nikolaos A Chatzizacharias Journal: World J Gastrointest Pathophysiol Date: 2020-04-12
Authors: J Busquets; S Martín; Ll Secanella; M Sorribas; N Cornellà; J Altet; N Peláez; M Bajen; T Carnaval; S Videla; J Fabregat Journal: Langenbecks Arch Surg Date: 2022-07-04 Impact factor: 2.895
Authors: Christoph A Fink; Mirco Friedrich; Pia-Elena Frey; Lukas Rädeker; Alexander Leuck; Thomas Bruckner; Manuel Feisst; Solveig Tenckhoff; Christina Klose; Colette Dörr-Harim; Jens Neudecker; André L Mihaljevic Journal: BMC Surg Date: 2018-10-29 Impact factor: 2.102
Authors: Teresa Macarulla; Andrew E Hendifar; Chung-Pin Li; Michele Reni; Hanno Riess; Margaret A Tempero; Amylou C Dueck; Marc F Botteman; Chinmay G Deshpande; Eleanor J Lucas; Do-Youn Oh Journal: Pancreas Date: 2020-03 Impact factor: 3.243